DOCSLIB.ORG

AOGD Bulletin November 2019.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AOGD Bulletin November 2019.Indd AOGDAOGD BULLETINBULLETIN Volume 19 I November 2019 I Monthly Issue 7 I Price `30 Only Enlightening the Path for Next Generation of Gynaecologists Dedicated Issue: Contraception AAOGDOGD SSECRETARIATECRETARIAT Department of Obstetrics & Gynaecology, 3076, Teaching Block, IIIrd Floor, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029 Vol.19, No.7; November,Tel.: 2019 011-26546603, 26593221 E-mail: [email protected] 1 Website: www.aogd.org 2 AOGD Bulletin AOGD Bulletin Volume 19 • Monthly Issue 7 • November 2019 AOGD Executive Committee 2019-20 President Vice President Hon. Secretary Dr Sunesh Kumar Dr Ashok Kumar Dr Vatsla Dadhwal President Patrons Dr Sunesh Kumar Dr D Takkar Dr Kamal Buckshee Vice President Dr Neera Agarwal Dr Ashok Kumar Dr Sheila Mehra Hony. Secretary Dr S K Bhandari Contents Dr Vatsla Dadhwal Dr S N Mukherjee Dr Swaraj Batra • Oral Contraceptive Pills (OCPs) 7 Scientifi c Advisors Dr Urmil Sharma Dr Dipika Deka Dr V L Bhargava Swati Agrawal, Dr Anu Handa Dr Neerja Bhatla Dr K K Roy Advisors • Non-Oral Hormonal Contraceptive Methods 11 Dr Neena Malhotra Dr Alka Kriplani Dr Amita Suneja Jyoti Meena, Garima Patel Treasurer Dr Chitra Raghunandan Dr Rohini Sehgal Dr Pratima Mittal • Intrauterine Devices 15 Dr SB Khanna Editor J B Sharma, Rinchen Zangmo Dr Sharda Jain Dr J B Sharma Dr Shubha Sagar Trivedi • PPIUCD: An Effective Method of Postpartum Contraception 21 Web Editor Dr Sudha Salhan Dr Juhi Bharti Dr Suneeta Mittal Monika Gupta, Sunita Malik, Harshita Dr Usha Manaktala Joint Secretaries • Contraception for Adolescent 25 Dr K Aparna Sharma Ex Offi cio Shefali Gupta, Niharika Dhiman Executive Past Presidents Co-Editors Dr P Chadha (1990-94) Dr Reeta Mahey Dr Neera Agarwal (1994-97) • Emergency Contraception 35 Dr Vanamail Dr Maya Sood (1997-99) Garima Patel, Kusum Lata, Vidushi Kulshrestha Clinical Secretaries Dr D Takkar (1999-2001) Dr Vidushi Kulshreshtha Dr Sudha Salhan (2001-03) • Contraception in Elderly 38 Dr Rajesh Kumari Dr Swaraj Batra (2003-05) Ankita Priya, Ruchi Srivastava Dr N B Vaid (2005-06) Scientifi c Committee Dr S S Trivedi (2006-07) • Contraception in Medical Disorders 40 Dr Neeta Singh Dr Suneeta Mittal (2007-08) Dr Garima Kachhawa Dr I Ganguli (2008-09) Sandhya Jain, Kanika Kalra Dr Seema Singhal Dr Shashi Prateek (2009-10) Dr Jyoti Meena Dr U Manaktala (2010-11) • Post Abortion and Post Delivery Abortion 47 Finance Committee Dr Neerja Goel (2011-12) Aditi Jindal, Anupama Bahadur Dr Reva Tripathi Dr C Raghunandan (2012-13) Dr N B Vaid Dr Alka Kriplani (2013-14) • Female Sterilization: Revisited 51 Dr Manju Puri Dr U P Jha (2014-15) Dr Abha Singh Dr Pratima Mittal (2015-16) Rupali Dewan, Sarita Singh, Ankita Jain Dr Sunesh Kumar Dr Sudha Prasad (2016-17) Dr Shalini Rajaram Dr Shalini Rajaram (2017-18) • Long Active Reversible Contraceptives 55 Dr Sudha Prasad Immediate Past President Swati Shivhare, Richa Vatsa Dr Pratima Mittal (2018-2019) Dr U P Jha Dr Abha Singh • Journal Scan 57 Mr Pankaj (CA) Immediate Past Secretary Rinchen Zangmo, Juhi Bharti Executive Members (2018-2019) Dr Anita Sabharwal Dr Kiran Aggarwal • Proceedings of AOGD Monthly Clinical Meeting 59 Dr Achla Batra President Elect (2020-2021) Dr Asmita Rathore Dr Mala Srivastava • The Maze of Knowledge and Pictorial Quiz 60 Dr Bela Makhija Richa Vatsa Dr Dinesh Kansal Vice President FOGSI Dr Gauri Gandhi Dr Sudha Prasad Dr Indu Chawla Chairpersons Dr Kiran Guleria Disclaimer AOGD Sub-Committees Dr Manash Biswas The advertisements in this bulletin are not a warranty, endorsement or approval of the products Dr Manju Khemani or services. The statements and opinions contained in the articles of the AOGD Bulletin are solely Dr Manju Khemani Dr Manju Puri Dr Manju Puri Dr Amita Suneja those of the individual authors and contributors, and do not necessarily refl ect the opinions or Dr Mala Srivastava Dr Achla Batra recommendations of the publisher. The publisher disclaims responsibility of any injury to persons Dr Ranjana Sharma Dr Kiran Aggarwal or property resulting from any ideas or products referred to in the articles or advertisements. Dr Renu Mishra Dr Anita Rajorhia Dr Reva Tripathi Dr Jyotsna Suri Plagiarism Disclaimer Dr Rupali Dewan Dr Manisha Kumar Any plagiarism in the articles will be the sole responsibility of the authors, the editorial board or Dr S N Basu Dr Reema Bhatt publisher will not be responsible for this. Dr Sangeeta Gupta Dr Richa Sharma Dr Shalini Rajaram Dr Susheela Gupta Publisher/Printer/Editor Dr Suman Lata Dr Surveen Ghumman Dr J B Sharma on behalf of Association of Obstetricians & Gynecologists of Delhi. Dr Abha Sharma Dr A G Radhika Printed at Process & Spot C-112/3, Naraina Industrial Area, Phase-1, New Delhi 110 028 AOGD Secretariat Published from Department of Obstetrics and Gynecology Department of Obstetrics and Gynecology 3076, Teaching Block, IIIrd Floor All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029 All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029 Editor Tel No: 011-26546603, 26593221 Dr J B Sharma Email: [email protected] Ph. No. 011-26546603; Email: [email protected] www.aogd.org Total number of pages = 64 Vol.19, No.7; November, 2019 3 From the President’s Pen Welcome to November issue of AOGD Monthly Bulletin. This issue is devoted to Contraception. Last decade had seen lot of advancement in the fi eld of Contraception. Current issue tends to cover latest in the fi eld. Not only information useful to exam gong PGs but also to practising physician. AICOG conference is fast approaching,do send your papers. Dr Sunesh Kumar President, AOGD 4 AOGD Bulletin From the Secretary’s Desk Dear Friends, Warm wishes from AOGD Secretariat, AIIMS. Continuing on the path of enlightenment for the Next Gen Gynecologists, various academic activities were organized in the month of October. A master class on over active Bladder (OAB) was organized under the aegis of Urogynecology subcommittee, AOGD on 19th October. Under the aegis of Endoscopy committee, AOGD, a certifi cate course on Endosuturing was organised on 21st & 22nd October. A public lecture on “Breast Cancer Awareness” organized under the aegis of Oncology committee AOGD was well attended on 30th October. For the purpose of public awareness and community outreach on the burning issue of contraception, this current issue on “Contraception” will cover the basic concepts as well as recent advances on this topic. We look forward to your continued support. Warm regards, Dr Vatsla Dadhwal Hon. Secretary Monthly Clinical Meeting Monthly Clinical Meet will be held at MAMC & LN Hospital, New Delhi on Friday, 29th November, 2019 from 04:00pm to 05:00pm. Vol.19, No.7; November, 2019 5 From the Editor’s Desk Dr J B Sharma Dr Reeta Mahey Dr P Vanamail Dr Vidushi Kulshreshtha Editor Co-Editors We are pleased to write the editorial desk for this issue of AOGD Bulletin on special topic of ‘contraception’, with the satisfaction that previous issue on ‘Endoscopic surgery in Gynaecology’ ably edited by Prof. KK Roy and team, was very much appreciated by fellow AOGD colleagues as is clear from numerous appreciation phone calls, emails and letters. Population explosion is the single most important factor hindering growth and development of the world as a whole and India in particular. We have to conquer this monster of uncontrolled population explosion for the necessary development of the country as the resources are limited. Even the Honorable Prime Minister accepted this challenge at his red fort address on Independence Day. In this dedicated issue of “Contraception” we have relevant articles on all aspects of contraception. We have an interesting article on “Oral Contraception Pills” by Dr Swati Agarwal and Dr Anu Handa from LHMC which shall guide our esteemed colleagues about the importance of this most important method of contraception which is highly under-utilized in India. There is need to popularize oral pills in India and to reduce the unmet need of contraception. We also have an interesting article on “Non-Oral Hormonal Contraception” by Dr Jyoti Meena and Dr Garima Patel from AIIMS for the benefi t of our esteemed readers. Intrauterine contraceptive device remains a method of choice for many Indian women and is particularly suited for most Indian rural women as it is a onetime procedure. There is an article on this topic by myself and Dr Rinchan from AIIMS. We have another interesting article on “Postpartum IUCD” by Dr Sunita Malik, Dr Monika Gupta and Dr Harshita from VMMC & Safdarjung Hospital, New Delhi which is very relevant as Government of India is very keen to promote PPIUCD and it’s particularly suited for our women. We have a useful article on ‘Emergency Contraception’ by Dr Garima Patel, Dr Kusum Lata and Dr Vidushi Kulshrestha from AIIMS for the readers. We also have clinically useful article on other relevant topics on contraception like “Contraception in Adolescents” by Dr Niharika Dhiman and Dr Shefali Gupta from LHMC and “Contraception in Elderly Women” by Dr Ruchi Srivastava and Dr Ankita Priya from Noida. We also have interesting and useful article on “Contraception Medical Disorder” by Dr Sandhya Jain and Dr Kanika Kalra from UCMS and on “Post Abortion and Post Delivery Contraception” by Dr Anupama Bahadur and Dr Aditi Jindal from AIIMS, Rishikesh. Dr Rupali Dewan, Dr Sarita Singh and Dr Ankita Jain also enlightens us on “Female Sterilization” which is the most popular terminal method used by Indian women for contraception. We also have an interesting fl ow chart on “Long-acting Reversible Contraception (LARC)” by Dr Richa Vatsa and Dr Swati Shivhare and Journal scan by Dr Juhi Bharti and Dr Richen Zangmo from AIIMS, New Delhi.
Load more

Recommended publications
  • University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth
    University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 08-10-2021 Financial support for the printing of this thesis was kindly provided by the Dutch Medicines Evaluation Board and UMCG/GUIDE.
    [Show full text]
  • Lactational Amenorrhea Method
    Lactational Amenorrhea Method Dr. Raqibat Idris [email protected] From Research to Practice: Training in Sexual and Reproductive Health Research 2017 Objectives of presentation • Define Lactational Amenorrhea Method (LAM) • Understand the mechanism of action of LAM • Know the efficacy of LAM • Know and describe the 3 criteria for LAM • Know the indication and contraindications for LAM • Know the focus and timing of counselling for LAM • List the advantages, disadvantages and health benefits of LAM • Know the elements of programming necessary for the provision of quality LAM services Introduction Breastfeeding delays the return of a woman’s fertility in the first few months following childbirth. Women who breastfeed are less likely to ovulate in this period. When compared with women who breastfeed partially or who do not breastfeed at all, women who breastfeed more intensively are less likely to have a normal ovulation before their first menstrual bleed postpartum (Berens et al., 2015). In a consensus meeting in Bellagio, Italy in 1998, scientists proposed that women who breastfeed fully or nearly fully while they remain amenorrhoeic in the first 6 months postpartum experience up to 98% protection from pregnancy. This formed the basis for the Lactational Amenorrhea Method and has since then been tested and confirmed by other studies (Berens et al., 2015; Van der Wijden et al., 2003; WHO, 1999). Berens P, Labbok M, The Academy of Breastfeeding Medicine. ABM Clinical Protocol #13: Contraception During Breastfeeding, Revised 2015. Breastfeeding Medicine. 2015 Feb;10(1):3-12. The World Health Organization multinational study of breast-feeding and lactational amenorrhea. III.
    [Show full text]
  • Efficacy of a Selective Estrogen Receptor Modulator: 'Ormeloxifene' in Management of Dysfunctional Uterine Bleeding
    JSAFOG CLINICALEfficacy PRACTICEof a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding Efficacy of a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding 1Tapan Kumar Bhattacharyya, 2Anusyua Banerji 1Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly, Uttar Pradesh India 2Senior Resident, RG Kar Medical College, Kolkata, West Bengal, India Correspondence: Tapan Kumar Bhattacharyya, Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly-243202, Uttar Pradesh, India, Phone: 09748236960, e-mail: [email protected] Abstract Background: Ormeloxifene, a third generation selective estrogen receptor modulator, has been claimed to ameliorate symptoms of DUB. This study was undertaken to compare the efficacy of ormeloxifene and norethisterone. Methods: 180 cases of DUB, who have completed child bearing and are above 35 years, were randomly assigned ormeloxifene, progesterone and iron groups. Ormeloxifene group received ormeloxifene for 12 weeks. Norethisterone group received norethisterone for 12 days in every cycle for six cycles. Iron was given as 60 mg of elemental iron daily. Before starting drug therapy, ultrasound, office hysteroscopy and endometrium sampling for histopathology was obtained and repeated at end of follow-up. The side effects and complications of drug ormeloxifene were noted and relief of symptoms and patient acceptability were compared with norethisterone. Results: 81.7% in the ormeloxifene administered subjects marked relief of symptoms with significant reduction of PBAC scores, reduction of blood clots, and rise in hemoglobin levels. Side effects/complications included amenorrhea, urinary incontinence and genital prolapse. The ease of administration of ormeloxifene facilitated compliance and acceptability.
    [Show full text]
  • Sterilization and Abortion Policy Billing Instructions
    Sterilization and Abortion Policy Billing Instructions Table of contents Table of contents ...................................................................................................................................... 1 Hysterectomy ............................................................................................................................................ 2 Acknowledgement forms ..................................................................................................................... 2 Prior authorization requirements ......................................................................................................... 2 Covered services ................................................................................................................................... 2 Intrauterine Devices and Subdermal Implants ......................................................................................... 4 Family planning: sterilization .................................................................................................................... 4 Prior authorization requirements ......................................................................................................... 5 Covered services ................................................................................................................................... 5 Abortion .................................................................................................................................................... 6 Claim
    [Show full text]
  • NFP Related Research ……………………………………………
    1 Winter/Spring 2000 ● Vol. 11, Nos. 1 and 2 Richard J. Fehring, DNSc, RN, Marquette University College of Nursing In this issue NFP Related Research ……………………………………………. 2 Pregnancy and Breastfeeding …………………………………….. 8 Contraception ……………………………………………………… 11 Research Briefs …………………………………………………….. 14 Under the Microscope ……………………………………………... 19 The Effectiveness of Natural Family Planning, Robert T. Kambic, MSH Current Medical Research is a publication of the Natural Family Planning Program of the United States Conference of Catholic Bishops.© Washington, DC: USCCB, 2011. The managing editor is Theresa Notare, PhD, Assistant Director. Permission is granted to reproduce in whole or in part, in print and/or electronically, with the following statement: Current Medical Research, NFPP/US Conference of Catholic Bishops, Washington, DC, volume # (year): page#. Used with permission. 2 Natural Family Planning United States Physicians Underestimate Effectiveness of Natural Family Planning A recent study conducted by researchers at the University of Missouri-Columbia, found that 79% of physicians in Missouri estimated the best possible effectiveness of natural family planning for avoiding pregnancy to be less than 91%. Sixty-five percent of those surveyed ranked the actual effectiveness of NFP to be 70% or less.1 The purpose of the study was to determine physicians' knowledge and practices of modern methods of NFP. The researchers assumed that modern methods of NFP are important for medical practice in order to help women and couples avoid or achieve pregnancy. A one page questionnaire on knowledge and practice of NFP was created by the researchers and mailed to 840 randomly selected physicians in Missouri. While 69% of the 547 respondents saw women for reproductive needs, only 46% mentioned NFP to at least some women when discussing family planning issues.
    [Show full text]
  • F.8 Ethinylestradiol-Etonogestrel.Pdf
    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]
  • Guidance for Management of Troublesome Vaginal Bleeding with Progestogen-Only Long-Acting Reversible Contraception (LARC)
    Guidance for management of troublesome vaginal bleeding with progestogen-only long-acting reversible contraception (LARC) Initial consultation Management of troublesome bleeding Provide accurate Information about expected bleeding patterns, 1. Exclude other causes emphasising that troublesome bleeding is likely to improve with time: Pregnancy, sexually transmitted infections (STIs) including chlamydia, liver-enzyme Implant: 1/5 amenorrhoea, 3/5 infrequent, irregular bleeding, 1/5 frequent or inducing medications (implant only) and vaginal, cervical or uterine pathology prolonged bleeding; approximately 1/2 with frequent or prolonged bleeding will 2. If no suspicion of another cause for bleeding improve after three months. Reassure this is ‘normal’ and not harmful Hormonal IUD: frequent spotting/bleeding common in first 3-5 months; either 3. Advise medication management amenorrhoea, light irregular or light regular bleeding common after six months. Ensure no contraindications and explain risks and side effects DMPA Injection: 1/2 amenorrhoea, 1/6 infrequent irregular bleeding, 1/3 frequent/ prolonged bleeding; amenorrhoea increases over time. 4. Advise that the implant or hormonal IUD can be removed any time or the depot medroxyprogesterone acetate (DMPA) injection discontinued. Be proactive in offering management advice for troublesome bleeding Actively encourage review of troublesome bleeding. First line options: • A combined hormonal contraceptive1 taken continuously or cyclically for three months • Five day course of NSAID2 such as mefenamic acid 500mg bd-tds • Five day course of tranexamic3 acid 500mg bd, particularly if bleeding is heavy Second line options Contraindications include: 1 migraine with aura, personal and family history of venous thromboembolism, risk factor for cardiovascu- With low level, anecdotal or conflicting evidence: lar disease and smoking >35 years of age, active breast cancer.
    [Show full text]
  • Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection
    Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection Semen specimen 12 weeks after your vasectomy: Twelve weeks (3 months) after your vasectomy, you should collect a semen specimen in the container provided to you by the Urology Department. It is recommended that you have at least 20 ejaculations within the 12-week period after your vasectomy. Depending on the results of your initial sample, you may be asked by your physician to provide another sample. You must utilize an alternate method of contraception until cleared by your physician. You are considered fertile following vasectomy until, as per the American Urological Assn. recommendations, at least one semen analysis shows no fertile sperm. On rare occasions, the vasectomy can fail and the vas deferens tubes can rejoin. Your semen specimen can be brought by yourself to the Urology Clinic only if: It can be in the laboratory within one hour of collection, and It is kept at room temperature during that time. It is suggested, however, that you create your semen specimen while you are at the Urology Clinic. Your semen specimen deposit should be scheduled in advance by Kathy Stevens: call 434-924-9548 or 434- 924-9560. Please note the following important instructions and guidelines for semen collection: The sample should be collected after a minimum of 2 days, and a maximum of 7 days, of sexual abstinence. If you choose to collect the specimen at home, it must be collected in a clean specimen container with a secure lid, such as one with a screw-on cap.
    [Show full text]
  • Hormonal Iuds Are Small ‘T- Shaped’ Plastic Devices That Are Inserted Into the Uterus (Womb)
    HORMONAL INTRAUTERINE DEVICES (IUDs) – (Mirena and Kyleena) What are the hormonal intrauterine devices (IUDs)? The hormonal IUDs are small ‘T- shaped’ plastic devices that are inserted into the uterus (womb). The hormonal IUDs contains progestogen. This is a synthetic version of the hormone progesterone made naturally by the ovaries. The hormonal IUDs have a coating (membrane) that controls the slow release of progestogen into the uterus. There are two different hormonal IUDs available in Australia. They are sold as Mirena and Kyleena. How effective are the hormonal IUDs? The hormonal IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 years. They can be used for contraception until 55 years of age if inserted when you are 45 years of age or older. How does the hormonal IUD work? IUDs affect the way sperm move and survive in the uterus (womb), stopping sperm from meeting and fertilising an egg. IUDs can also change the lining of the uterus, making it difficult for a fertilised egg to stick to the lining to start a pregnancy. The hormonal IUDs also work by thickening the fluid around the cervix (opening to the uterus/womb). This helps to prevent sperm from entering. Sometimes the hormonal IUDs can also stop the ovaries from releasing an egg. What are differences between Mirena and Kyleena hormonal IUDs? Both Mirena and Kyleena are very effective methods of contraception that last for up to 5 years. Mirena is 99.9% effective and Kyleena is 99.7% effective. Mirena may be used until 55 years of age if inserted when you are 45 years of age or older, whereas Kyleena needs to be replaced every 5 years for all ages.
    [Show full text]
  • Natural Family Planning
    your guide to natural family planning Helping you choose the method of contraception that is best for you natural family planning naturalnatural family family planning planning naturalnatural familynatural family planning planning natural family planning natural family planning familynatural family planning natural family planning natural familynatural planning family planning natural family planning planningnatural family planning natural family planning familynatural planning familynatural family planning planning 2 3 What is the menstrual cycle? Natural family The menstrual cycle is the time from the first day of your period to the day before your next period starts. The average length of the menstrual planning cycle is around 28 days, although many women have longer or shorter cycles and this is normal. This booklet gives information on how natural Regardless of how long or short the cycle is, family planning can help you to avoid pregnancy. ovulation (when the ovaries release an egg) will usually happen around 10–16 days before the Fertility awareness involves being able to identify start of the next period. During your menstrual the signs and symptoms of fertility during cycle: the menstrual cycle so you can plan or avoid O Eggs develop in your ovaries and usually one is pregnancy. released. O The mucus in the cervix (entrance to the uterus – womb) changes to allow sperm to Contents What is the menstrual cycle? .......................................................3 How can I work out how long my menstrual cycle How does natural
    [Show full text]